Loading
Lung cancer researcher who led the pooled analysis showing that entrectinib shrinks NTRK fusion-positive tumours of many kinds, and who studied how ROS1 and NTRK cancers escape targeted drugs.
Robert Doebele was first author of the 2020 Lancet Oncology integrated analysis of the entrectinib trials in NTRK fusion-positive solid tumours, part of the evidence for the drug's tumour-agnostic approval. As a physician-scientist at the University of Colorado he described resistance mechanisms in ROS1- and NTRK-driven lung cancers and helped establish patient-derived models of oncogene-addicted cancers.
| Title | Journal | Year |
|---|---|---|
| Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials | The Lancet Oncology | 2020 |
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares Non-small-cell lung cancer and the tag lung.